AstraZeneca buys a CDK9 cancer drug portfolio

AstraZeneca ($AZN) has swooped in to pick up a portfolio of new cancer therapy from Germany's Probiodrug. The pharma giant paid an undisclosed sum for the biotech's CDK9 program, which includes a lead molecule and some backups. AstraZeneca says the portfolio has potential both for cancer as well as inflammatory diseases. Cyclin-dependent kinases regulate cell cycle progression. CDK 4/6 therapies at Pfizer ($PFE) and Novartis ($NVS) have attracted the bulk of investigators' attention in the field until now. Hendrik Liebers, CFO of Probiodrug, says the deal leaves the company free to focus exclusively on Alzheimer's. Release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.